ERBB2 and breast carcinoma: The overexpression of HER2- in breast cancer can be overcome by developing DOX encapsulated into anti-HER2- monoclonal antibodies decorated O-succinyl chitosan graft Pluronic® F127 (OCP) copolymer nanoparticles.